当前位置: 首页 >> 检索结果
901. Myocardial Perfusion Imaging With PET: A Head-to-Head Comparison of 82Rubidium Versus 15O-water Tracers Using Invasive Coronary Measurements as Reference.
作者: Simon Winther.;Laust Dupont Rasmussen.;Salma Raghad Karim.;Jelmer Westra.;Jonathan Nørtoft Dahl.;Jacob Hartmann Søby.;Louise Nissen.;Fabian Bøgild Lomstein.;Morten Würtz.;Jens Munch Sundbøll.;June Anita Ejlersen.;Jesper Mortensen.;Lars Poulsen Tolbod.;Hanne Maare Søndergaard.;Nicolaj Christopher Lyng Hansson.;Mette Nyegaard.;Rebekka Vibjerg Jensen.;Michael Alle Madsen.;Evald Høj Christiansen.;Lars Christian Gormsen.;Morten Böttcher.
来源: Circ Cardiovasc Imaging. 2025年18卷6期e017479页
Myocardial perfusion imaging by positron emission tomography (PET) is recommended as a first-line test in stable patients with chest pain symptoms and as a selective second-line test after an abnormal coronary computed tomography angiography (CTA). It is, however, unknown whether the use of Rubidium-82 (82Rb) versus [15O]H2O (15O-water) affects the diagnostic performance in coronary artery disease (CAD). The aim of this study was to compare 82Rb-PET versus 15O-water-PET head-to-head for diagnosing obstructive CAD.
902. The PARADIGM Study: Procedural Augmented Reality Assessment in a 3-Dimensional Image-Guided Modality.
作者: Alan Hanley.;Andrew Locke.;Jagmeet Singh.;Patricia Tung.;William J Hucker.;Robert D'Angelo.;Jennifer N Avari Silva.;Jonathan R Silva.;Andre d'Avila.;Gregory F Michaud.
来源: Circ Arrhythm Electrophysiol. 2025年18卷4期e013222页
The CommandEP system v2 (Sentiar, St. Louis, MO) utilizes an augmented reality headset (Magic Leap, Plantation, FL) to display a real-time 3-dimensional electroanatomic map, catheter locations, and ablation catheter contact force data to the electrophysiologist using a hands-free interface. In the intra-PARADIGM study (Procedural Augmented Reality Assessment in a 3-Dimensional Image Guided Modality), the impact of the CommandEP system on the electrophysiologist's ability to navigate accurately, intraprocedural communications, and system usability were studied.
903. Corticosteroids in Fulminant Myocarditis Associated With Viral Infection.
作者: Florent Huang.;Enrico Ammirati.;Maharajah Ponnaiah.;Santiago Montero.;Nadia Aïssaoui.;Albert Ariza Solé.;Martin Balik.;Eduardo Barge-Caballero.;Jeroen J H Bunge.;Hergen Buscher.;Clément Delmas.;Dirk W Donker.;Christoph Fisser.;Guillaume Franchineau.;Justin Fried.;Francisco José Hernández-Pérez.;Joshua Ihle.;Jae-Seung Jung.;Teresa Lόpez-Sobrino.;Jamie McCanny.;Armand Mekontso Dessap.;Henrique Muglia.;Shinichiro Ohshimo.;Sunghoon Park.;Romain Persichini.;Beatriz Porral.;Roberto Roncon-Albuquerque.;Alessandro Sionis.;Pauline Yeung Ng.;Alain Combes.;Matthieu Schmidt.; .
来源: Circ Heart Fail. 2025年18卷5期e012399页 904. Angiography-Derived Microcirculatory Resistance in Detecting Microvascular Obstruction and Predicting Heart Failure After STEMI.
作者: Guanyu Lu.;Lei Zhao.;Keyao Hui.;Zhihui Lu.;Xiaoli Zhang.;Hai Gao.;Xiaohai Ma.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017506页
Microvascular obstruction (MVO) is associated with heart failure (HF) following ST-segment-elevation myocardial infarction. Angiography-derived microcirculatory resistance (AMR), a wire- and adenosine-free measure, may facilitate early assessment of microvascular function post-primary percutaneous coronary intervention. This study aimed to evaluate the ability of AMR to detect MVO and its prognostic value for predicting HF in patients with ST-segment-elevation myocardial infarction post-primary percutaneous coronary intervention.
906. Outcomes of Transcatheter Aortic Valve Replacement in Low-Risk Patients in the United States: A Report From the STS/ACC TVT Registry.
作者: Andrew M Vekstein.;Zachary K Wegermann.;Pratik Manandhar.;Michael J Mack.;David J Cohen.;G Chad Hughes.;J Kevin Harrison.;Tsuyoshi Kaneko.;Samir R Kapadia.;Konstantinos Stathogiannis.;William F Fearon.;Suzanne Arnold.;Andrzej S Kosinski.;Martin B Leon.;Wayne B Batchelor.;Vinod H Thourani.;Sreekanth Vemulapalli.
来源: Circulation. 2025年151卷16期1134-1146页
Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption.
908. Evolution of Cardiac Damage Following SAVR in Asymptomatic Severe Aortic Stenosis.
作者: Simon Jacob.;Sébastien Hecht.;Lionel Tastet.;Marie-Ange Fleury.;Kathia Abdoun.;Jérémy Bernard.;Mylène Shen.;Romain Capoulade.;Marie Arsenault.;Élisabeth Bédard.;Nancy Côté.;Marie-Annick Clavel.;Philippe Généreux.;Philippe Pibarot.
来源: Circ Cardiovasc Interv. 2025年18卷6期e014860页 909. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
910. Two-Year Clinical Outcomes in Female and Male Patients After Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease.
作者: Pier Pasquale Leone.;Luca Testa.;Antonio Greco.;Lee C Yan.;Diego Milazzo.;Susanna Benincasa.;Dario Gattuso.;Bernardo Cortese.; .
来源: Circ Cardiovasc Interv. 2025年18卷6期e014814页 913. Sex-Specific Impact of Angiotensin Receptor Blockers on the Progression of Aortic Stenosis in Patients With Hypertension: Results From the HYTAS Study.
作者: Karolanne Demers.;Kathia Abdoun.;Philippe Pibarot.;Lionel Tastet.;Mulham Ali.;Erwan Salaun.;Paul Poirier.;Andréanne Powers.;Jordi Sanchez Dahl.;Jonathan Beaudoin.;Marie-Annick Clavel.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017913页 914. Atypical Presentation of an Increasingly Recognized Disease: Transthyretin Amyloidosis Presenting With 18F-Fluorodeoxyglucose Uptake on Cardiac Positron Emission Tomography and Focal Late Gadolinium Enhancement on Cardiac Magnetic Resonance.
作者: Kyla Brezitski.;Karen Flores Rosario.;Han W Kim.;Johana R Fajardo.;Michel G Khouri.;Salvador Borges-Neto.;Ravi Karra.
来源: Circ Heart Fail. 2025年18卷6期e012002页 916. Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.
作者: Xiong Guo.;Chong Huang.;Ling Zhang.;Guangyu Hu.;Yunhui Du.;Xiyao Chen.;Fangfang Sun.;Tongzheng Li.;Zhe Cui.;Congye Li.;Yongzhen Guo.;Wenjun Yan.;Yunlong Xia.;Shan Wang.;Hui Liu.;Zhiyuan Liu.;Zhen Lin.;Xinyi Wang.;Zhengyang Wang.;Fuyang Zhang.;Ling Tao.
来源: Circulation. 2025年151卷23期1651-1666页
Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored.
917. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
918. Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes.
作者: Eric J Kort.;Nazish Sayed.;Chun Liu.;Gema Mondéjar-Parreño.;Jens Forsberg.;Emily Eugster.;Sean M Wu.;Joseph C Wu.;Stefan Jovinge.
来源: Circulation. 2025年151卷20期1436-1448页
Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.
919. Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.
作者: Milind Y Desai.;Anjali Owens.;Sara Saberi.;Andrew Wang.;Kathy Wolski.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;Mark Zenker.;Mark Sherrid.;Jeffrey B Geske.;David Fermin.;Srihari S Naidu.;Kathy Lampl.;Steven E Nissen.; .
来源: Circ Genom Precis Med. 2025年18卷3期e005100页 920. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
|